[go: up one dir, main page]

WO2013100500A1 - Composition pharmaceutique pour le traitement du cancer, comprenant un peptide, le 5-fluorouracile, et des cellules dendritiques matures - Google Patents

Composition pharmaceutique pour le traitement du cancer, comprenant un peptide, le 5-fluorouracile, et des cellules dendritiques matures Download PDF

Info

Publication number
WO2013100500A1
WO2013100500A1 PCT/KR2012/011291 KR2012011291W WO2013100500A1 WO 2013100500 A1 WO2013100500 A1 WO 2013100500A1 KR 2012011291 W KR2012011291 W KR 2012011291W WO 2013100500 A1 WO2013100500 A1 WO 2013100500A1
Authority
WO
WIPO (PCT)
Prior art keywords
mature dendritic
cancer
dendritic cells
fluorouracil
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/011291
Other languages
English (en)
Korean (ko)
Inventor
배외식
김상두
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sungkyunkwan University
Original Assignee
Sungkyunkwan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sungkyunkwan University filed Critical Sungkyunkwan University
Publication of WO2013100500A1 publication Critical patent/WO2013100500A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to a pharmaceutical composition for treating cancer, comprising a WKYMVm peptide having a sequence of SEQ ID NO: 1, and comprising 5-fluorouracil and / or mature dendritic cells.
  • the present invention has been made to solve the above problems in the prior art, comprising a WKYMVm peptide having a sequence of SEQ ID NO: 1, 5-fluorouracil and / or mature dendritic cells (mature dendritic) It is an object of the present invention to provide a pharmaceutical composition for treating cancer comprising an effective amount of cells).
  • the present invention provides a pharmaceutical composition for treating cancer comprising an effective amount of a WKYMVm peptide having a sequence of SEQ ID NO: 1 and 5-fluorouracil.
  • the present invention provides a pharmaceutical composition for treating cancer comprising an effective amount of the WKYMVm peptide having a sequence of SEQ ID NO: 1 and mature dendritic cells.
  • the present invention also provides a pharmaceutical composition comprising an effective amount of a WKYMVm peptide having a sequence of SEQ ID NO: 1, 5-fluorouracil, and mature dendritic cells.
  • the composition is characterized in that it is used to suppress cancer derived from colon cancer or lymph cells.
  • the present invention provides a method of increasing the anti-cancer treatment effect by using a combination of WKYMVm peptide having a sequence of SEQ ID NO: 1 and 5-fluorouracil.
  • the present invention provides a method of increasing the anti-cancer treatment effect by co-administration of WKYMVm peptide having a sequence of SEQ ID NO: 1 and mature dendritic cells.
  • the present invention provides a method of increasing the anti-cancer treatment effect by concurrently administering the WKYMVm peptide having a sequence of SEQ ID NO: 1, 5-fluorouracil and mature dendritic cells.
  • Concomitant administration of 5-fluorouracil and / or mature dendritic cells, comprising the WKYMVm peptide according to the present invention can effectively reduce side effects and resistance caused by anticancer drugs because it can increase the immunity of the body and reduce the amount of anticancer drugs.
  • it is expected to be applicable to the treatment of cancer because it can significantly increase the anticancer effect.
  • the type of anticancer agent can be freely used to treat various types of cancer.
  • 1 is a schematic diagram of a method of administering the WKYMVm peptide, 5-fluorouracil, mature dendritic cells.
  • Figure 2 shows the results of measuring the anticancer effect of WKYMVm peptide, 5-fluorouracil, mature dendritic cells alone and in combination administration.
  • Figure 3 shows the results of measuring the effect of cancer cell death induced by WKYMVm peptide, 5-fluorouracil, mature dendritic cells alone and in combination.
  • Figure 4 shows the results of measuring the effect of inducing the migration of immune cells to tumor tissue by co-administration of WKYMVm peptide, 5-fluorouracil, mature dendritic cells.
  • FIG. 5 shows the effect of anti-CD8 antibody, anti-CD4 antibody and anti-asialo-GM1 antibody on the effect of inducing the migration of immune cells into tumor tissue by coadministration of WKYMVm peptide, 5-fluorouracil, and mature dendritic cells. It is a figure which shows the result of having measured.
  • Figure 6 shows the results of measuring the anticancer effect of CD8 T lymphocytes and NK cells induced by the co-administration of WKYMVm peptide, 5-fluorouracil, and mature dendritic cells.
  • Fig. 7 shows the results of measuring the effect of the combined administration of WKYMVm peptide, 5-fluorouracil, and mature dendritic cells on the amount of cytokines in cancer tissues or peripheral blood.
  • Fig. 8 shows the results of measuring cancer metastasis inhibitory effect of WKYMVm peptide, 5-fluorouracil, and mature dendritic cell co-administration.
  • Fig. 9 shows the results of measuring anticancer effects of WKYMVm peptide, 5-fluorouracil, and mature dendritic cell co-administration.
  • the inventors have previously described peptide ligands (Trp-Lys-Tyr-Met-Val-D-Met-NH 2 : SEQ ID NO: 1, hereinafter, “WKYMVm that increase leukocyte cells such as monocytes, neutrophils, etc.).
  • Peptides (Bae et al., 1999, J. Leukoc. Biol. 65, 241-248). Therefore, the present inventors have completed the present invention by studying a method of increasing the anticancer effect while reducing the amount of the anticancer agent by simultaneously using an anticancer agent while promoting an immune response using the WKYMVm peptide.
  • 5-fluorouracil 5-fluorouracil
  • thymine a precursor of DNA, which inhibits DNA synthesis of cancer cells and shows anticancer effects.
  • side effects such as bone marrow depression and diarrhea.
  • dendritic cells have been suggested to be able to be used for immune chemotherapy by promoting the immune response in the body, many studies have been conducted, but the situation is still insufficient in the anti-cancer effect.
  • the present inventors tried to use WKYMVm peptide and dendritic cells that can promote the immune response in the body and 5-fluorouracil, an anticancer agent, for use in anticancer treatment.
  • administration of 5-fluorouracil and / or mature dendritic cells in combination with WKYMVm peptide, 5-fluorouracil, or mature dendritic cells alone increases the volume of cancer. It was confirmed that it can be reduced by about 5 times (see Example 1), and in other examples, it was confirmed that the metastasis of cancer can be inhibited by 5 times or more through co-administration. It was confirmed that the survival rate can be significantly increased (see Examples 6 and 7).
  • the present invention includes a WKYMVm peptide having a sequence of SEQ ID NO: 1, and provides a method of enhancing anti-cancer treatment effect by concurrently administering 5-fluorouracil and / or mature dendritic cells. do.
  • the present invention provides a pharmaceutical composition for treating cancer comprising a WKYMVm peptide having a sequence of SEQ ID NO: 1, an effective amount of 5-fluorouracil and / or mature dendritic cells to provide.
  • a pharmaceutical composition for treating cancer comprising a WKYMVm peptide having a sequence of SEQ ID NO: 1, an effective amount of 5-fluorouracil and / or mature dendritic cells to provide.
  • a pharmaceutical composition for treating cancer comprising a WKYMVm peptide having a sequence of SEQ ID NO: 1, an effective amount of 5-fluorouracil and / or mature dendritic cells to provide.
  • the type of cancer to which the pharmaceutical composition for treating cancer of the present invention can be applied.
  • it can be used to suppress colon cancer or cancer derived from lymphoid cells.
  • the pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable carrier.
  • the pharmaceutically acceptable carrier may include physiological saline, polyethylene glycol, ethanol, vegetable oil, isopropyl myristate, and the like, but is not limited thereto.
  • Another aspect of the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a WKYMVm peptide having a sequence of SEQ ID NO: 1, comprising 5-fluorouracil and / or mature dendritic cells as an active ingredient
  • a method of treating cancer is provided by administering a pharmaceutically effective amount to a subject.
  • an individual means a subject in need of treatment of a disease, and more specifically, a human, or a non-human primate, a mouse, a rat, a dog, a cat, a horse, a cow, and the like.
  • the pharmaceutically effective amount in the present invention may be variously adjusted in the range depending on the weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and severity of the disease of the patient. Do.
  • the preferred dosage of the pharmaceutical composition of the present invention depends on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration, and the duration, and may be appropriately selected by those skilled in the art. However, preferably, it is administered at 0.001 to 100 mg / kg body weight per day, more preferably 0.01 to 30 mg / kg body weight. Administration may be administered once a day or may be divided several times.
  • WKYMVm peptide, 5-fluorouracil, and / or mature dendritic cells having the sequence of SEQ ID NO: 1 of the present invention are preferably 0.0001 to 10% by weight, based on the total weight of the total composition, preferably May be present in an amount from 0.001 to 1% by weight.
  • the pharmaceutical composition of the present invention can be administered to mammals such as mice, mice, livestock, humans, and the like by various routes.
  • the method of administration is not limited, and may be administered by oral, rectal, or intravenous, intramuscular, subcutaneous, intrauterine dural, or intra cerbroventricular injection.
  • mice treated with nothing, WKYMVm peptide, 5-FU, or mature dendritic cells alone or in combination of the two groups were divided and administered with the experimental group. And the volume of the cancer was quantified using the following formula.
  • a schematic diagram of the experimental procedure is shown in FIG. 1, and the experimental results are shown in FIG. 2.
  • the volume of cancer (mm 3) length (mm) X width (mm) 2/2
  • Example 2 To determine whether the anticancer effect of the combination of WKYMVm peptide, 5-fluorouracil (5-FU), and mature dendritic cell (mDC) is due to induction of apoptosis, the same method as in Example 1 39 days later, the cancer was removed from the mouse, fixed with 10% neutral phosphate buffered formalin (NBF), and then cut into several layers and stained with paraffin. For morphological analysis, stained with hematoxylin and eosin (H & E) and observed through light microscopy. For immunological analysis, anti-murine cleaved caspase-3 antibody or anti-murine FAS antibody was used.
  • NPF neutral phosphate buffered formalin
  • TUNEL staining, FAS and Caspase-3 staining all showed similar results.
  • WKYMVm peptide or mature dendritic cells alone the cells were almost dead, and when treated with 5-FU alone, some of the cells were dead.
  • 5-FU alone some of the cells were dead.
  • WKYMVm peptide, 5-FU, and mature dendritic cells almost all of the cells were confirmed to be dead.
  • co-administration of KYMVm peptide, 5-FU, and mature dendritic cells was confirmed to induce apoptosis and kill cancer cells.
  • rat anti-mouse CD8 antibodies rat anti-mouse asialo-GM1 antibodies, or rat anti-mouse CD4 antibodies to confirm that CD8 T lymphocytes and natural killer (NK) cells do not influence each other to gather around cancer.
  • 100 ⁇ g of each was intraperitoneal injection one day prior to subcutaneous injection of cancer into the mouse, the day of subcutaneous injection, and 5 days after subcutaneous injection. And stained in the same manner as above and observed through a fluorescence microscope. The results are shown in FIG.
  • CD8 T lymphocytes were not induced around the cancer, but NK cells were confirmed to be collected around the cancer.
  • anti-asialo-GM1 antibody treated NK cells did not induce cancer, but CD8 T lymphocytes gathered around cancer, and anti-CD4 antibody treated CD8 T lymphocytes and NK cells. It was confirmed that the induced around.
  • rat anti-mouse CD8 antibody rat anti-mouse asialo- 100 ⁇ g of the GM1 antibody or the rat anti-mouse CD4 antibody was intraperitoneally injected in the same manner as in Example 3, and then the volume of the cancer was measured by date. The results are shown in FIG.
  • interferon-gamma IFN-gamma
  • IL-12 interleukin-12
  • rat anti-mouse CD8 antibody administration of 100 ⁇ g of rat anti-mouse CD8 antibody, rat anti-mouse asialo-GM1 antibody, or rat anti-mouse CD4 antibody in the same manner as in Example 3 resulted in a sharp reduction in the amount of interferon-gamma and interleukin-12. I could confirm that.
  • CT-26 cell line was injected into the tail of the mouse and WKYMVm peptide, 5-FU, and mature dendritic cells were co-administered for 2 weeks, followed by the same method as in Example 2. Lungs were stained and observed with hematoxylin and eosin (H & E). The results are shown in FIG.
  • the pharmaceutical composition for cancer treatment comprising the WKYMVm peptide according to the present invention and containing an effective amount of 5-fluorouracil and / or mature dendritic cells can reduce the amount of anticancer agent by enhancing the body's immunity, Side effects and resistance can be effectively reduced.
  • the pharmaceutical composition for cancer treatment comprising the WKYMVm peptide according to the present invention and containing an effective amount of 5-fluorouracil and / or mature dendritic cells can reduce the amount of anticancer agent by enhancing the body's immunity, Side effects and resistance can be effectively reduced.
  • anticancer drugs when combined with various types of anticancer drugs can significantly increase the anticancer effect, it can be used as a pharmaceutical composition for treating various types of cancer.
  • composition comprising peptide, 5-fluorouracil, and mature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/KR2012/011291 2011-12-26 2012-12-21 Composition pharmaceutique pour le traitement du cancer, comprenant un peptide, le 5-fluorouracile, et des cellules dendritiques matures Ceased WO2013100500A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110142340A KR101361445B1 (ko) 2011-12-26 2011-12-26 펩타이드, 5-플루오로우라실, 및 성숙수지상세포를 포함하는 암 치료용 약학적 조성물
KR10-2011-0142340 2011-12-26

Publications (1)

Publication Number Publication Date
WO2013100500A1 true WO2013100500A1 (fr) 2013-07-04

Family

ID=48697876

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/011291 Ceased WO2013100500A1 (fr) 2011-12-26 2012-12-21 Composition pharmaceutique pour le traitement du cancer, comprenant un peptide, le 5-fluorouracile, et des cellules dendritiques matures

Country Status (2)

Country Link
KR (1) KR101361445B1 (fr)
WO (1) WO2013100500A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9730984B2 (en) 2012-05-11 2017-08-15 Gemvax & Kael Co., Ltd. Composition for preventing or treating rheumatoid arthritis
US9907838B2 (en) 2013-04-19 2018-03-06 Gemvax & Kael Co., Ltd. Composition and methods for treating ischemic damage
US9937240B2 (en) 2014-04-11 2018-04-10 Gemvax & Kael Co., Ltd. Peptide having fibrosis inhibitory activity and composition containing same
US10034922B2 (en) 2013-11-22 2018-07-31 Gemvax & Kael Co., Ltd. Peptide having angiogenesis inhibitory activity and composition containing same
US10039811B2 (en) 2012-05-11 2018-08-07 Gemvax & Kael Co., Ltd. Anti-inflammatory peptides and composition comprising the same
US10383926B2 (en) 2013-06-07 2019-08-20 Gemvax & Kael Co., Ltd. Biological markers useful in cancer immunotherapy
US10463708B2 (en) 2014-12-23 2019-11-05 Gemvax & Kael Co., Ltd. Peptide for treating ocular diseases and composition for treating ocular diseases comprising same
US10561703B2 (en) 2013-06-21 2020-02-18 Gemvax & Kael Co., Ltd. Method of modulating sex hormone levels using a sex hormone secretion modulator
US10662223B2 (en) 2014-04-30 2020-05-26 Gemvax & Kael Co., Ltd. Composition for organ, tissue, or cell transplantation, kit, and transplantation method
US10835582B2 (en) 2015-02-27 2020-11-17 Gemvax & Kael Co. Ltd. Peptide for preventing hearing loss, and composition comprising same
US10898540B2 (en) 2016-04-07 2021-01-26 Gem Vax & KAEL Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
US10967000B2 (en) 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
US11015179B2 (en) 2015-07-02 2021-05-25 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
US11058744B2 (en) 2013-12-17 2021-07-13 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102576410B1 (ko) 2020-11-09 2023-09-08 충남대학교산학협력단 바실러스 균주와 5-fu를 유효성분으로 하는 대장암 치료용 약학 조성물
EP4591864A1 (fr) 2022-09-22 2025-07-30 Samsung Medical Foundation Composition pharmaceutique pour la destruction de vaisseaux sanguins tumoraux
WO2024063569A1 (fr) 2022-09-22 2024-03-28 (의) 삼성의료재단 Composition pharmaceutique pour perturber des vaisseaux sanguins tumoraux
KR20240041258A (ko) 2022-09-22 2024-03-29 (의) 삼성의료재단 종양 혈관 파괴용 약학 조성물
KR20240041259A (ko) 2022-09-22 2024-03-29 (의) 삼성의료재단 종양 혈관 파괴용 약학 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080071194A (ko) * 2005-12-23 2008-08-01 주식회사 포스코 펩타이드 함유 항암제
KR20110121208A (ko) * 2010-04-30 2011-11-07 경북대학교 산학협력단 수지상 세포를 포함하는 신세포암의 치료용 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080071194A (ko) * 2005-12-23 2008-08-01 주식회사 포스코 펩타이드 함유 항암제
KR20110121208A (ko) * 2010-04-30 2011-11-07 경북대학교 산학협력단 수지상 세포를 포함하는 신세포암의 치료용 조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KIM, H. ET AL.: "Granulocyte function is stimulated by a novel hexapeptide, WKYMVm, in chemotherapy-treated cancer patients.", EXPERIMENTAL HEMATOLOGY., vol. 34, 2006, pages 407 - 413 *
LEE, H. ET AL.: "Trp-Lys-Tyr-Met-Val-Met stimulates phagocytosis via phospholipase D- dependent signaling in mouse dendritic cells.", EXPERIMENTAL AND MOLECULAR MEDICINE., vol. 36, no. 2, 2004, pages 135 - 144 *
NAGASAKI, E. ET AL.: "Combined Treatment With Dendritic Cells and 5-fluorouracil Elicits Augmented NK Cell-mediated Antitumor Activity Through the Tumor Necrosis Factor- alpha Pathway.", JOURNAL OF IMMUNOTHERAPY., vol. 33, no. 5, June 2010 (2010-06-01), pages 467 - 474 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11857607B2 (en) 2012-05-11 2024-01-02 Gemvax & Kael Co., Ltd. Anti-inflammatory peptides and composition comprising the same
US10960056B2 (en) 2012-05-11 2021-03-30 Gemvax & Kael Co., Ltd. Anti-inflammatory peptides and composition comprising the same
US9907837B2 (en) 2012-05-11 2018-03-06 Gemvax & Kael Co., Ltd. Composition for preventing or treating cachexia
US11369665B2 (en) 2012-05-11 2022-06-28 Gemvax & Kael Co., Ltd. Anti-inflammatory peptides and composition comprising the same
US9844584B2 (en) 2012-05-11 2017-12-19 Gemvax & Kael Co., Ltd. Composition for preventing or treating sepsis
US10039811B2 (en) 2012-05-11 2018-08-07 Gemvax & Kael Co., Ltd. Anti-inflammatory peptides and composition comprising the same
US12168039B2 (en) 2012-05-11 2024-12-17 Gemvax & Kael Co., Ltd. Anti-inflammatory peptides and composition comprising the same
US9730984B2 (en) 2012-05-11 2017-08-15 Gemvax & Kael Co., Ltd. Composition for preventing or treating rheumatoid arthritis
US12156902B2 (en) 2012-05-11 2024-12-03 Gemvax & Kael Co., Ltd. Anti-inflammatory peptides and composition comprising the same
US10967000B2 (en) 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
US9907838B2 (en) 2013-04-19 2018-03-06 Gemvax & Kael Co., Ltd. Composition and methods for treating ischemic damage
US10383926B2 (en) 2013-06-07 2019-08-20 Gemvax & Kael Co., Ltd. Biological markers useful in cancer immunotherapy
US10561703B2 (en) 2013-06-21 2020-02-18 Gemvax & Kael Co., Ltd. Method of modulating sex hormone levels using a sex hormone secretion modulator
US10034922B2 (en) 2013-11-22 2018-07-31 Gemvax & Kael Co., Ltd. Peptide having angiogenesis inhibitory activity and composition containing same
US11058744B2 (en) 2013-12-17 2021-07-13 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
US9937240B2 (en) 2014-04-11 2018-04-10 Gemvax & Kael Co., Ltd. Peptide having fibrosis inhibitory activity and composition containing same
US10662223B2 (en) 2014-04-30 2020-05-26 Gemvax & Kael Co., Ltd. Composition for organ, tissue, or cell transplantation, kit, and transplantation method
US11077163B2 (en) 2014-12-23 2021-08-03 Gemvax & Kael Co., Ltd. Peptide for treating ocular diseases and composition for treating ocular diseases comprising same
US10463708B2 (en) 2014-12-23 2019-11-05 Gemvax & Kael Co., Ltd. Peptide for treating ocular diseases and composition for treating ocular diseases comprising same
US10835582B2 (en) 2015-02-27 2020-11-17 Gemvax & Kael Co. Ltd. Peptide for preventing hearing loss, and composition comprising same
US11015179B2 (en) 2015-07-02 2021-05-25 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
US10898540B2 (en) 2016-04-07 2021-01-26 Gem Vax & KAEL Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same

Also Published As

Publication number Publication date
KR20130074325A (ko) 2013-07-04
KR101361445B1 (ko) 2014-02-12

Similar Documents

Publication Publication Date Title
WO2013100500A1 (fr) Composition pharmaceutique pour le traitement du cancer, comprenant un peptide, le 5-fluorouracile, et des cellules dendritiques matures
JP3723206B2 (ja) ムラミルペプチドとサイトカインとを組み合わせることを特徴とするヒトに用いる治療用組成物
Hunter et al. Production of gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID mice: regulation by interleukin-10, interleukin-12, and tumor necrosis factor alpha
Vujanovic et al. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues.
CN101631850B (zh) 增加和转移造血干细胞的方法
Ogawa et al. Multiple roles of interferon-γ in the mediation of interleukin 12-induced tumor regression
US5382427A (en) Use of IL-4 to treat solid tumors
US20110218169A1 (en) Pirfenidone/Toll-Like Receptor (TLR) Agonist Compounds and Methods of Treating Neutropenia
Lee et al. Interferon gamma induction during oral tolerance reduces T-cell migration to sites of inflammation
Mastino et al. Combination therapy with thymosin α1 potentiates the anti‐tumor activity of interleukin‐2 with cyclophosphamide in the treatment of the lewis lung carcinoma in mice
KR20020016844A (ko) 반응성 산소 대사산물 저해제를 이용한 세포독성 림프구의활성화 및 보호
US20070190025A1 (en) Method to enhance hematopoiesis
Pope et al. 7-Allyl-8-oxoguanosine (loxoribine) inhibits the metastasis of B16 melanoma cells and has adjuvant activity in mice immunized with a B16 tumor vaccine
US5716612A (en) Use of IL-4 for potentiation of chemotherapeutic agents
CN115282280A (zh) TGF-β1信号抑制剂的新用途
WO2025048206A1 (fr) Cellules lymphoïdes innées de type 2 à activité cytotoxique, leur procédé de production et utilisation associée
WO2025121806A1 (fr) Composition pharmaceutique pour la prévention ou le traitement du cancer, comprenant un agent de dégradation de btk et un inhibiteur de mettl3
Wu et al. Anti‐tumor Effects of Interleukin‐4 and Interleukin‐5 against Mouse B Cell Lymphoma and Possible Mechanisms of Their Action
AU2003273758A1 (en) Treatment of allergic conditions by use of il 21
WO2020190071A1 (fr) Composition pharmaceutique destinée à la prévention ou au traitement du cancer, et son utilisation
Bakhiet Interferon-and Interleukin-12 Genes are Preferentially Expressed During Early Experimental African Trypanosomiasis and Suppressed by Denervation of the Spleen
Satoh et al. A murine plasmacytoma MOPC 104E resistant to cyclophosphamide is resistant to immunotherapy
BA32 TGF-B (pglml)
ZA200502301B (en) Treatment of allergic conditions by use of il21.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12862681

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12862681

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 12862681

Country of ref document: EP

Kind code of ref document: A1